Fenwick & West Represents Vysis in $355 Million Cash Tender Offer

October 24, 2001

Deal Announced: October 24, 2001
Web Posted: October 25, 2001

Abbott Laboratories and Vysis, Inc. today announced their definitive agreement for Abbott to acquire Vysis, a leading genomic disease management company that develops and markets clinical laboratory products that provide information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. The transaction is structured as an all-shares cash tender offer followed by a back-end merger, and is valued at approximately $355 million. Fenwick & West LLP represented Downers Grove, Illinois-based Vysis in the transaction.

F&W's transaction team was led by Douglas Cogen, Co-Chair of the Firm's Mergers & Acquisitions group, and John Kastelic, Corporate partner. Lynn Pasahow, a Fenwick partner and Vysis' outside patent litigation counsel, provided assistance on intellectual property matters, partner Scott Spector provided compensation and benefits advice and partner Mark Ostrau covered antitrust matters. F&W corporate associates Heidi Lamb and Alexandra Shin, intellectual property associate Patrick Toher and employee benefits associate Thomas Kim assisted with the transaction. Cogen commented, "This transaction again showcases Fenwick & West's M&A strength as well as its considerable expertise in biotechnology matters. We are very pleased to have represented Vysis, a cutting-edge biotech company developing clinical products that save lives." Abbott Laboratories was represented by the Chicago office of Skadden Arps.

Press inquiries regarding Fenwick & West's representation in this matter should be addressed to Doug Cogen, 415.875.2409.

Abbott Press Release: